Watch Omniscope in action.
Within the BAXERNA project, Omniscope quantifies the impact of M. tuberculosis mRNA vaccines on the immune system to elucidate their efficacy, aid in vaccine candidate prioritization, and validate patient response during Phase I clinical trial.
Omniscope uses science as a force for good to bring healthcare to everyone, everywhere.
CEO Vijay Vaswani presents Omniscope during the Startup Competition of South Summit Madrid.
In this study, Dr. Christian Brander demonstrates Omniscope OS-T platform's capacity to identify and track clonotypes of interest and measure disease and immunity signatures.
At the AIRR community meeting 6, Dr. Holger Heyn, co-founder Omniscope, presents our proprietary T cell (TCR) sequencing OS-T, reading up to 1 million T cells per sample
Startup Festival: Diagnostic Tools in Today's Healthcare Environment, featuring Dr. Holger Heyn and Lynnette Ang, co-founders of Omniscope.
